EGFR and neoplasm: More importantly, these inhibitors may fail to achieve effective accumulation at tumor sites, limiting their ability to adequately modulate the immunosuppressive TME.[26] Thus, while promising in concept, the CD73 inhibitors often lack tumor‐specific delivery mechanisms, reducing their impact on the immunosuppressive niches created by EGFR‐mutant tumors.